Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec Research Ltd
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving people with severe haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds. Ensayo clínico con sujetos con Hemofilia A Severa para determinar cómo de seguro es tomar una proteína experimental que reemplaza al factor VIII (conocido como rFVIIIFc) y cómo de efectivo es en la prevención y la interrupción de los sangrados
The primary objective of the study is to evaluate the long-term safety of rFVIIIFc in subjects with hemophilia A. El objetivo principal del estudio es evaluar la seguridad a largo plazo de rFVII...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving people with severe haemophilia A to look at how two different strengths of an experimental replacement factor VIII protein (known as rFVIIIFc) are processed by the body and how safe it is to take
The primary objective of the study is to characterize the PK of rFVIIIFc administered at vial strengths of 1000 and 3000 IU in subjects with severe hemophilia A.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving previously untreated patients with haemophilia B to look at how safe an experimental replacement factor IX protein (known as rFIXFc) is to take and how well it works to prevent and stop bleeds
The primary objective of the study is to evaluate the safety of rFIXFc in previously untreated subjects with severe hemophilia B.
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving previously untreated patients with haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds
The primary objective of the study is to evaluate the safety of rFVIIIFc in previously untreated subjects with severe hemophilia A.
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving children up to age of 12 years with severe hemophilia A, to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds
The primary objective of the study is to evaluate safety of rFVIIIFc in previously treated pediatric subjects with hemophilia A.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving people with severe haemophilia B to look at how safe an experimental replacement factor IX protein (known as rFIXFc) is to take and how well it works to prevent and stop bleeds
The primary objective of the study is to evaluate the long-term safety of rFIXFc in subjects with hemophilia B.
Country
None
organs
None
Specialty
None
unknown
More information